STERIS (STE)
(Real Time Quote from BATS)
$200.50 USD
+0.26 (0.13%)
Updated Apr 18, 2024 02:11 PM ET
2-Buy of 5 2
B Value C Growth B Momentum B VGM
Company Summary
Ohio-headquartered STERIS plc, develops, manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services. The legacy company was originally known as STERIS Corporation. On Nov 2, 2015, STERIS completed the acquisition of Synergy Health plc following which it was re-registered under the name – STERIS plc.
Currently, STERIS serves healthcare, pharmaceutical, research, industrial and governmental customers across the globe. The majority of STERIS’ revenues is derived from the healthcare and pharmaceutical industries. STERIS provides its products and services in more than 60 countries. The company’s ...
Company Summary
Ohio-headquartered STERIS plc, develops, manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services. The legacy company was originally known as STERIS Corporation. On Nov 2, 2015, STERIS completed the acquisition of Synergy Health plc following which it was re-registered under the name – STERIS plc.
Currently, STERIS serves healthcare, pharmaceutical, research, industrial and governmental customers across the globe. The majority of STERIS’ revenues is derived from the healthcare and pharmaceutical industries. STERIS provides its products and services in more than 60 countries. The company’s key areas of strategic focus include developing its customer base in Europe, the Middle East and the Asia Pacific region.
During its first-quarter fiscal 2022 earnings call, the company noted the addition of a new dental segment to its business operations. Henceforth, STERIS now operates through four segments — Healthcare, Applied Sterilization Technologies, Life Sciences and Dental.
Healthcare (62.2% of total revenues in FY23, up 8.4% from FY22): Effective Apr 1, the company’s legacy Healthcare Products and Healthcare Specialty Services arms were combined and reported as Healthcare. This biggest segment of STERIS includes Healthcare Products part of the business which offers infection prevention and procedural solutions for global healthcare providers. The Healthcare Specialty Services part comprises specialty services including hospital sterilization services, instrument and scope repairs and linen management.
Life Sciences (10.8%, up 2.2%): This segment offers capital equipment and consumable products and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities.
Applied Sterilization Technologies (AST) (18.4%, up 7.2%): This segment offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
The Dental segment (8.5%, up 16.6%).
STERIS divested the Synergy Health Healthcare Consumable Solutions ("HCS") business in fiscal 2018.
General Information
STERIS plc
70 Sir John Rogerson`s Quay
Dublin, L2 D02 R296
Phone: 353-1232-2000
Fax: 440-639-4457
Email: julie_winter@steris.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | March |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 5/8/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 2.43 |
Current Year EPS Consensus Estimate | 8.67 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/8/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 200.24 |
52 Week High | 254.00 |
52 Week Low | 180.54 |
Beta | 0.79 |
20 Day Moving Average | 573,310.62 |
Target Price Consensus | 240.60 |
4 Week | -14.16 |
12 Week | -6.80 |
YTD | -8.92 |
4 Week | -10.70 |
12 Week | -9.65 |
YTD | -13.50 |
Shares Outstanding (millions) | 98.81 |
Market Capitalization (millions) | 19,786.52 |
Short Ratio | NA |
Last Split Date | 8/25/1998 |
Dividend Yield | 1.04% |
Annual Dividend | $2.08 |
Payout Ratio | 0.24 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | 2/22/2024 / $0.52 |
Fundamental Ratios
P/E (F1) | 21.03 |
Trailing 12 Months | 23.42 |
PEG Ratio | NA |
vs. Previous Year | 9.90% |
vs. Previous Quarter | 9.36% |
vs. Previous Year | 14.77% |
vs. Previous Quarter | 3.97% |
Price/Book | 3.08 |
Price/Cash Flow | 10.61 |
Price / Sales | 3.66 |
3/31/24 | NA |
12/31/23 | 13.67 |
9/30/23 | 13.58 |
3/31/24 | NA |
12/31/23 | 7.68 |
9/30/23 | 7.62 |
3/31/24 | NA |
12/31/23 | 2.43 |
9/30/23 | 2.49 |
3/31/24 | NA |
12/31/23 | 1.49 |
9/30/23 | 1.55 |
3/31/24 | NA |
12/31/23 | 15.73 |
9/30/23 | 15.91 |
3/31/24 | NA |
12/31/23 | 10.48 |
9/30/23 | 10.52 |
3/31/24 | NA |
12/31/23 | 12.62 |
9/30/23 | 12.69 |
3/31/24 | NA |
12/31/23 | 65.06 |
9/30/23 | 62.65 |
3/31/24 | NA |
12/31/23 | 3.88 |
9/30/23 | 3.96 |
3/31/24 | NA |
12/31/23 | 0.50 |
9/30/23 | 0.54 |
3/31/24 | NA |
12/31/23 | 33.45 |
9/30/23 | 35.23 |